GlassScriptPhysician profile
Sameera Daud Ahmad
NPI 1073700381
$11,447.38
in general payments reported to CMS, 2019-2025
45 companies · $1,360 in 2025
The $1,360 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $667 · 2021: $3,246 · 2022: $1,593 · 2023: $1,404 · 2024: $2,900 · 2025: $1,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,188 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,435 · Education: $41.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,187.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,435.00 |
| Education | $41.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,312.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $1,867.07 | 2021-2025 | Korlym |
| Lilly USA, LLC | $1,051.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $482.43 | 2020-2025 | |
| Amgen INC. | $443.28 | 2019-2025 | Evenity, Tepezza, Prolia |
| Amneal Pharmaceuticals LLC | $427.94 | 2021-2025 | Unithroid |
| Abbvie INC. | $373.02 | 2020-2025 | Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.55 | 2021-2025 | Jardiance, Tradjenta |
| Medtronic, INC. | $308.14 | 2021-2025 | Minimed 780g |
| Merck Sharp & Dohme LLC | $300.51 | 2019-2023 | Steglujan, Steglatro, Segluromet |
| Dexcom, INC. | $286.49 | 2021-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $272.36 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $245.21 | 2020-2023 | Farxiga |
| Pfizer INC. | $200.28 | 2020-2023 | |
| Tandem Diabetes Care, INC. | $145.83 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $145.78 | 2019-2025 | |
| Insulet Corporation | $137.27 | 2023-2024 | Omnipod |
| Allergan, INC. | $110.73 | 2020 | |
| Abbott Laboratories | $84.50 | 2022-2025 | Freestyle Libre 3 |
| Cequr Corporation | $79.57 | 2021-2023 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $74.41 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $73.14 | 2022-2025 | Strensiq |
| Zealand Pharma US, INC. | $64.49 | 2021-2022 | |
| Acella Pharmaceuticals, LLC | $60.74 | 2024-2025 | NP Thyroid 60 |
| Rhythm Pharmaceuticals, INC. | $55.76 | 2024-2025 | Imcivree |
| Chiesi USA, INC. | $54.44 | 2024 | Mycapssa |
| Amarin Pharma, INC. | $54.08 | 2019-2022 | |
| Ibsa Pharma INC. | $48.52 | 2023-2025 | Licart, Flector, Tirosint |
| Recordati_rare_diseases_inc. | $45.72 | 2024 | Isturisa, Signifor Lar |
| Ascendis Pharma Endocrinology INC | $35.17 | 2023-2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $33.80 | 2025 | |
| Currax Pharmaceuticals LLC | $32.79 | 2023 | Contrave |
| Intuity Medical INC | $28.74 | 2022 | |
| Astellas Pharma US INC | $21.31 | 2024 | Veozah |
| Ascensia Diabetes Care US INC. | $20.05 | 2025 | |
| Beta Bionics, INC. | $20.00 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Vivus LLC | $18.83 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $17.46 | 2024 | |
| Amryt Pharma Holdings LTD | $17.20 | 2023 | Mycapssa |
| Amphastar Pharmaceuticals, INC. | $15.55 | 2024 | |
| Echosens North America, INC. | $14.82 | 2024 | Fibroscan |
| Acerus Pharmaceuticals Corporation | $14.26 | 2022 | |
| Horizon Therapeutics Plc | $13.53 | 2023 | Tepezza |
| Vistapharm, INC. | $12.00 | 2021 | |
| Becton, Dickinson and Company | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameera Daud Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.